🇺🇸 FDA
Patent

US 9846160

Ganglioside GD2 as a marker and target on cancer stem cells

granted A61KA61K2039/505A61K31/4192

Quick answer

US patent 9846160 (Ganglioside GD2 as a marker and target on cancer stem cells) held by The Board of Regents of the University of Texas System expires Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Dec 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61K31/4192, A61K31/4196, A61K39/39558